Q-omics provides the consensus-scored INSL6 profile across patient tissues and cancer cell-line models. INSL6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, INSL6 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, INSL6 RNA expression shows 11,063 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BLCA, KICH, and DLBC as cancer lineages where INSL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INSL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INSL6 survival associations across molecular data types. INSL6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INSL6 RNA expression–survival associations across cancer types. High INSL6 expression shows unfavorable associations in THYM and READ, but favorable associations in BLCA, BRCA, MESO and CESC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify BLCA as the clearest survival context for INSL6 RNA expression.
This table summarizes INSL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for INSL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INSL6 shows lower tumor expression in KICH, KIRC, COAD and LUSC and higher tumor expression in PRAD. The KICH box plot shows higher INSL6 RNA expression in normal versus tumor tissue (log2 FC = −0.323, t-test p < 0.001).
This table shows molecular features associated with INSL6 in patient tissues and cancer cell lines. In patient samples, INSL6 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, INSL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and KIDNEY.
